Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ADORA2A | P29274 | 1/20 | 0.54 |
| ▸ | ADORA1 | P30542 | 1/20 | 0.54 |
| ▸ | TLR7 | Q9NYK1 | 1/20 | 0.50 |
| ▸ | ADRB2 | P07550 | 1/20 | 0.50 |
| ▸ | IGF1R | P08069 | 4/20 | 0.47 |
| ▸ | BACE1 | P56817 | 1/20 | 0.46 |
| ▸ | MAPT | P10636 | 3/20 | 0.46 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.46 |
| ▸ | ELANE | P08246 | 1/20 | 0.45 |
| ▸ | PKM | P14618 | 1/20 | 0.45 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.45 |
| ▸ | NT5E | P21589 | 1/20 | 0.44 |
| ▸ | HPGD | P15428 | 1/20 | 0.42 |
| ▸ | RAB9A | P51151 | 1/20 | 0.42 |
| ▸ | GAA | P10253 | 1/20 | 0.42 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL28311336 | 0.79 | ADORA2A (0.55) | ADORA2AADORA1TLR7ADRB2IGF1R | |
| SCHEMBL693661 | 0.79 | NT5E (0.62) | ADORA2AADORA1TLR7ADRB2IGF1R | |
| SCHEMBL3300391 | 0.79 | BACE1 (0.66) | ADORA2AADORA1TLR7ADRB2IGF1R | |
| SCHEMBL11893019 | 0.79 | TLR7 (0.55) | ADORA2AADORA1TLR7ADRB2IGF1R | |
| SCHEMBL3962730 | 0.79 | ADORA2A (0.51) | ADORA2AADORA1TLR7ADRB2IGF1R | |
| SCHEMBL31473229 | 0.78 | CYP1A2 (0.58) | ADORA2AADORA1TLR7ADRB2BACE1 | |
| SCHEMBL423741 | 0.78 | CYP1A2 (0.58) | ADORA2AADORA1TLR7ADRB2BACE1 | |
| SCHEMBL30106724 | 0.78 | ADORA2A (0.54) | ADORA2AADORA1TLR7ADRB2IGF1R | |
| SCHEMBL2657337 | 0.78 | ADORA2A (0.54) | ADORA2AADORA1TLR7ADRB2IGF1R | |
| SCHEMBL30106738 | 0.78 | NCF1 (0.55) | ADORA2AADORA1TLR7ADRB2IGF1R |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8853243-B2 | Substituted cyclic hydroxamates as inhibitors of matrix metalloproteinases | INCYTE CORPORATION (US) | 2014-10-07 | — | — | US | disclosed |
| US-20110224189-A1 | SUBSTITUTED CYCLIC HYDROXAMATES AS INHIBITORS OF MATRIX METALLOPROTEINASES | INCYTE CORPORATION | 2011-09-15 | — | — | US | disclosed |
| EP-2264030-A1 | Substituted cyclic hydroxamates as inhibitors of matrix metalloproteinases | Incyte Corporation (US) | 2010-12-22 | — | — | EP | disclosed |
| US-7491724-B2 | Substituted cyclic hydroxamates as inhibitors of matrix metalloproteinases | INCYTE CORPORATION (US) | 2009-02-17 | — | — | US | disclosed |
| US-20050113344-A1 | Substituted cyclic hydroxamates as inhibitors of matrix metalloproteinases | INCYTE CORPORATION | 2005-05-26 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110224189-A1 | SUBSTITUTED CYCLIC HYDROXAMATES AS INHIBITORS OF MATRIX METALLOPROTEINASES | MMP25, MMP14, MMP9 | ADORA2A 2618/4885ADORA1 2428/4885TLR7 1917/4885 |
| US-20050113344-A1 | Substituted cyclic hydroxamates as inhibitors of matrix metalloproteinases | MMP25, MMP2, MMP14 | ADORA2A 2478/4885ADORA1 2039/4885TLR7 1851/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.